Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Internal appointment at UK MHRA as Ian Hudson named new chief exec

This article was originally published in Scrip

Executive Summary

Ian Hudson has been named the new head of the UK Medicines and Healthcare Products Regulatory Agency. Dr Hudson, currently the MHRA’s licensing director, will succeed Professor Sir Kent Woods when the latter steps down in September after almost 10 years as chief executive of the agency. Dr Hudson is well-known in regulatory and industry circles. He is the UK delegate to the European Medicines Agency’s Committee on Human Medicinal Products (CHMP) and has been the committee’s vice-chairman since October 2012.

You may also be interested in...



ConMed’s Ortho Franchise Prioritizes Pipeline Over External Growth

ConMed’s ambitions in orthopedics are to be the clinician’s support, develop differentiated offerings and avoid “me too” activity, before all notions of leading the market rankings.

Executives On The Move: Tech And Science Announcements At Orexo And Agios, And Board Changes At Accorda And RhoVac

Swedish pharma Orexo welcomes EVP, digital health and anti-cancer therapeutics firm Agios Pharmaceuticals announces Bristol-Myers Squibb exec as its next CSO. And a chair takes a seat at Accorda Therapeutics and RhoVac.

Leading Medtechs See Organic Growth Across A Market In Flux

In 2018, the top 100 publicly listed and reportable medical device technology companies had global sales spanning from over $30bn to some $100m in the lower reaches. As the latest In Vivo Medtech 100 ranking shows, many of the major changes in value sales were linked to company restructurings. But there were some impressive organic gains too.

UsernamePublicRestriction

Register

SC021978

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel